Robyn A. Jordan

Robyn A. Jordan

Auto-generated profile, based on publicly available information

Robyn A. Jordan

University of North Carolina, Department of Psychiatry, 1101 Weaver Dairy Rd Ste 102, Chapel Hill 27514, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2023 in International Journal of Drug Policy
Verified
Journal Article
Closed access
LML. Madeline McCrary
L. Madeline McCrary
MCMary E. Cox
Mary E. Cox
KRKate E. Roberts
Kate E. Roberts
AKAndrea K. Knittel
Andrea K. Knittel
RJRobyn A. Jordan
Robyn A. Jordan
ASAsher J. Schranz
Asher J. Schranz

1 June 2020 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Closed access
AFAnna Forsythe
Anna Forsythe
GLGareth Lewis
Gareth Lewis
RJRobyn Jordan
Robyn Jordan
George ThompsonGeorge Thompson
George Thompson
Aim: This study evaluated burden of illness in immunocompromised patients with systemic mycoses (SM) eligible for itraconazole treatment, specifically, histoplasmosis, blastomycosis and aspergillosis. Methods: A cross-sectional study used an electronic medical record network integrating information from 30 US hospitals, including >34 million patients, to evaluate burden and healthcare resource utilization over 6 months following initiation of antifungal therapy. Results: Symptomatic burden experienced by each of the otherwise healthy or age >65 or immunosuppressed cohorts receiving antifungal therapy for SM was comparable but significantly greater in cancer or HIV patients and transplant recipients. Across groups, there was substantially higher healthcare resource utilization in patients with SM versus matched controls without SM. Conclusion: The total impact of SM is particularly severe in high-risk or vulnerable populations.